Veeva Systems bags order from three new customers

With the macro U.S. economy starting to show signs of recovery, the life sciences sector is reaching for new remedies to cure its financial ills. Pharmaceutical and biotechnology companies are adopting breakthrough technologies like multi-tenant SaaS CRM solutions to help reduce costs, improve operations, and increase sales. As evidence of this trend, Veeva Systems, the leader in SaaS CRM solutions for the global life sciences industry, has recently signed three new customers. In addition, a top ten pharmaceutical company has completed the full deployment of Veeva CRM™ system to over 750 users.

Matt Wallach, executive vice president and general manager of Veeva Systems, stated “It is no secret that the traditional pharma sales model is under attack, forcing companies to change and innovate at a rapid pace. We are seeing that only the very latest, multi-tenant SaaS technology allows them to be nimble enough to be successful when experimenting and deploying new sales strategies.”

The new SaaS adopters each went through an extensive selection process before choosing Veeva CRM. They cited the product’s out-of-the-box functionality for a wide range of users, its flexibility – both in terms of licensing and system configuration – and its scalability to easily handle widely fluctuating user numbers. However, all three life sciences companies noted that cost was one of the biggest factors influencing their decision to choose the award-winning SaaS CRM application.

According to a study by Tripletree and the Software and Information Industry Association (SIIA), SaaS deployments can have a total cost of ownership at least five to ten times less than installed software.

“Life science organizations are seeking ways to improve their business flexibility while cutting profit-draining overhead. Built on the world’s most mature multi-tenant SaaS architecture, Veeva CRM offers an easy way to significantly improve sales effectiveness while saving money at the same time,” concluded Wallach.